What is the typical BPC-157 dosage for injury healing?

For injury healing via subcutaneous injection, the most commonly reported research dose is 250–500mcg per day injected near the injury site. For systemic use, some protocols use twice-daily injections. For gut healing via oral administration, higher doses of 500–1000mcg per day are typically used since oral bioavailability is lower than subcutaneous. Cycles typically run 4–12 weeks.

BPC-157 Guide: Dosage, Benefits & Healing Science (2026)

Q: Is BPC-157 safe and has it been tested in humans?

BPC-157 has been studied in 15+ human trials, mostly small in scale and focused on gut conditions. No human toxicity has been published and no genotoxicity has been found in animal studies. The FDA granted fast-track designation to BPC-157 (formulated as PL-10) for inflammatory bowel disease, which marks the first US regulatory acknowledgment of its therapeutic potential. BPC-157 remains a research compound and is not FDA-approved for any indication.

Shotlee

Download on theApp Store

Become aBeta Tester

What Is BPC-157?

BPC-157 stands for Body Protection Compound-157. It is a stable pentadecapeptide — a sequence of exactly 15 amino acids (GEPPPGKPADDAGLV) — originally derived from a naturally occurring protein found in human gastric juice. Unlike most peptides, BPC-157 is remarkably stable in gastric acid, which is why it can survive oral ingestion and produce local gut effects that injectable peptides typically cannot.

Research into BPC-157 spans decades, originating primarily from Croatian researcher Stjepan Sikiric at the University of Zagreb. The compound has been tested in animal models of tendon injury, IBD, nerve damage, traumatic brain injury, and more — consistently demonstrating accelerated tissue healing across organ systems. The number 157 refers to its position in the sequence of the parent gastric protein.

Critically, BPC-157 is available in two salt forms: the acetate salt (the original and most studied research form) and the arginine salt (marketed as more stable in aqueous solution and better suited for oral use). The acetate form dominates most published research, but both appear to share the same active amino acid sequence.

Amino Acids

GEPPPGKPADDAGLV — the exact sequence that makes BPC-157 so stable and versatile across delivery routes.

15+

Human Trials

More human trial data than most research peptides — primarily focused on gut conditions including IBD and fistulas.

FDA

Fast-Track (IBD)

PL-10 formulation granted FDA fast-track designation for inflammatory bowel disease — the HEAL trial marks US regulatory acknowledgment.

How BPC-157 Works: Mechanisms

Growth Factor Upregulation

BPC-157 upregulates growth hormone receptors in tendon fibroblasts, increasing the tissue's sensitivity to endogenous GH. It also activates focal adhesion kinase (FAK) and paxillin signaling — two critical proteins in the mechanotransduction cascade that drives tendon and ligament repair. This is why BPC-157 shows such consistent results in tendon injury models: it essentially amplifies the body's own healing signal at the repair site.

Angiogenesis (VEGF Pathway)

One of BPC-157's most important actions is the promotion of new blood vessel formation through VEGF (Vascular Endothelial Growth Factor) upregulation. Tendons, ligaments, and cartilage are notoriously avascular — poor blood supply is the primary reason these tissues heal so slowly. BPC-157 drives angiogenesis into the injury zone, delivering oxygen, nutrients, and immune cells that would otherwise be absent.

Nitric Oxide System Modulation

BPC-157 modulates the nitric oxide (NO) system in a nuanced way — it upregulates eNOS (endothelial NO synthase, which produces beneficial vascular NO) while counteracting the excessive iNOS (inducible NO synthase) activity associated with tissue damage and inflammation. This NO system balance is critical for blood vessel relaxation, tissue perfusion, and inflammatory resolution at healing sites.

Gut Cytoprotection

In the GI tract, BPC-157 protects the mucosal barrier through multiple parallel mechanisms: it promotes mucosal repair, prevents gastric ulcer formation (even against NSAID-induced damage), reduces intestinal permeability ("leaky gut"), and modulates motility. This is its most documented clinical application — studied in IBD, fistulas, and gut damage from various insults. The gastric stability of BPC-157 means oral dosing directly delivers the compound to gut tissue.

Routes of Administration & Dosage

BPC-157's gastric stability is one of its most unusual properties and gives it a therapeutic flexibility that most peptides lack. Three primary routes are used in research protocols, each with different target tissue distributions and appropriate dose ranges.

Subcutaneous Injection

The most studied and reliable route for systemic and localized injury healing. Injected subcutaneously — either near the injury site (local) or in the abdomen (systemic). Fast absorption into circulation.

• Dose: 250–500mcg/day
• Timing: Once or twice daily
• Cycle: 4–12 weeks
• Best for: tendon, ligament, nerve

Oral Administration

Uniquely viable due to BPC-157's gastric acid stability. Produces primarily local gut effects as the compound acts directly on GI mucosa. Lower systemic bioavailability than SQ, hence higher doses.

• Dose: 500–1000mcg/day
• Timing: On empty stomach
• Cycle: 4–8 weeks
• Best for: IBD, leaky gut, GERD

Intranasal

Less established route being explored for CNS and neuroprotective applications. The nasal-brain pathway allows direct delivery to cerebrospinal fluid, bypassing the blood-brain barrier. Limited formal research exists on this route.

• Dose: Under investigation
• Timing: Varies by protocol
• Cycle: Not well-established
• Best for: TBI, brain protection (exploratory)

BPC-157 Effects by System

Musculoskeletal

Achilles tendon: Accelerated healing documented in multiple animal models — fibroblast proliferation, collagen organization, and biomechanical tensile strength all improved vs. controls.
Rotator cuff: Studied in rat models of supraspinatus injury showing enhanced tendon-to-bone integration at the repair site — directly relevant to common shoulder injuries.
Ligaments: Medial collateral ligament healing improved in rat models; common anecdotal use for ACL/PCL support post-surgery.
Bone healing: Some data on improved fracture healing through periosteum cell activation and angiogenesis at the callus.

Gastrointestinal

IBD and fistulas: Most documented human use. Small trials show reduced inflammation, improved mucosal integrity, and fistula closure rates in Crohn's disease patients.
NSAID-induced gut damage: BPC-157 completely prevented gastric ulcer formation from indomethacin in rodent studies — even when given after the NSAID.
Intestinal permeability: Reduces "leaky gut" by strengthening tight junctions in gut epithelium — relevant to systemic inflammation and autoimmune conditions.
Motility disorders: Normalizes gastric motility in both hypomotility and hypermotility models — rare bidirectional regulatory effect.

Neurological

Peripheral nerve repair: Sciatic nerve crush injury models show faster functional recovery with BPC-157 — relevant for nerve damage from surgery, trauma, or compression.
Brain protection: Showed neuroprotective effects in traumatic brain injury and stroke models — reduces lesion size and improves functional outcomes.
Dopaminergic modulation: Research suggests BPC-157 modulates dopamine receptor sensitivity — explored for relevance to addiction recovery and withdrawal symptom management.

Anti-Inflammatory & Systemic

Systemic anti-inflammatory: Reduces pro-inflammatory cytokines (TNF-α, IL-6) without the immunosuppressive side effects of corticosteroids — no evidence of impairing healing.
Blood pressure regulation: Via NO system modulation — counteracts both NO-deficiency hypertension and NO-excess hypotension in preclinical models.
Cardiac protection: Some data on BPC-157 reducing cardiac damage post-ischemia — a smaller effect than TB-500 but present nonetheless.

BPC-157 Stacking: Pairing for Synergy

BPC-157's most popular pairing is with TB-500 — the classic healing stack. The two peptides address tissue repair through genuinely different mechanisms: BPC-157 handles angiogenesis, growth factor signaling, and the vascular environment for healing; TB-500 handles the structural actin dynamics and cell migration that physically rebuild tissue. The synergy is well-supported by mechanistic logic and is the most reported peptide combination in the research community.

BPC-157 is also combined with GHK-Cu in chronic repair and anti-aging protocols — BPC-157 handles acute healing signals while GHK-Cu handles the longer-term collagen remodeling and gene expression changes. Some users on GLP-1 medications add BPC-157 to manage GI side effects, a mechanistically plausible application given its documented gut cytoprotective effects.

BPC-157 + TB-500 (Recovery Stack)

The most popular peptide stack in existence. Complementary non-overlapping mechanisms produce faster soft tissue healing than either compound alone.

• BPC-157: 250–500mcg/day SQ
• TB-500: 2–5mg 2x/week (loading), then 2–5mg/week
• Can inject at same site sequentially

BPC-157 + GHK-Cu (Systemic Repair)

Acute + chronic repair combination. BPC-157 drives acute healing response; GHK-Cu handles long-term tissue remodeling, collagen architecture, and anti-aging gene regulation.

• BPC-157: 250–500mcg/day SQ
• GHK-Cu: 1–2mg/day or EOD SQ
• Popular in longevity and post-surgical contexts

Frequently Asked Questions

What is BPC-157 and what does it do?

BPC-157 (Body Protection Compound-157) is a stable 15 amino acid sequence derived from human gastric juice that promotes healing across multiple organ systems. It accelerates tendon and ligament repair through growth factor upregulation and angiogenesis, heals gut tissue through cytoprotective mechanisms, promotes nerve repair, and modulates the nitric oxide system for anti-inflammatory effects. Its unusual gastric acid stability means it can be taken orally for gut-specific effects or injected subcutaneously for systemic healing.

What is the typical BPC-157 dosage for tendon or ligament injury?

The most commonly reported research dose for musculoskeletal injury is 250–500mcg per day administered subcutaneously, either near the injury site for local effect or in the abdomen for systemic distribution. Some protocols use twice-daily injections at lower single doses. Typical cycles run 4–12 weeks. For gut conditions via oral administration, higher doses of 500–1000mcg per day are used due to lower systemic bioavailability from the oral route.

Is BPC-157 safe and has it been tested in humans?

BPC-157 has been tested in over 15 human trials, primarily focused on gut conditions. No human toxicity has been published. Animal studies show no genotoxicity. The FDA granted fast-track designation to a BPC-157 formulation (PL-10) for inflammatory bowel disease, marking the first US regulatory engagement with the compound. BPC-157 remains a research compound and is not FDA-approved for any indication. As with all research peptides, use is self-directed and off-label.

Track Your BPC-157 Protocol with Shotlee

Log every injection — dose, site, timing, and response — so you have real data on what your healing protocol is actually doing.

Start Tracking Free